drugset

drugset / Trial / NCT00002337

A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease

NCT00002337 ↗

Phase 1 Completed 56 enrolled Otsuka America Pharmaceutical

Open-labelTreatment

Summary

To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vesnarinone	Small molecule	—	Oral

Indications